Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 280 participants.

Also called NCT03169985

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 280 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03169985
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03169985. Randomized; double masking; primary purpose treatment. Start 2017-07-12 (actual); primary completion 2027-01-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque
Acronym
Rosuzet-IVUS
Intervention (Drug)
Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day
Intervention (Drug)
Rosuvastatin 20 mg orally once a day
Lead sponsor
Samsung Medical Center (class: other)
Collaborator
Hanmi Pharmaceutical co., ltd. (class: other)

Record details

Record id
cardio:ct-nct03169985
Content hash
36b92efafa391adde7b4f05a80b644a6b4a887d668d7108a3ee895bd02d350c1